Paolo Strati1, Sattva S Neelapu2. 1. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 429, Houston, TX, 77030, USA. 2. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 429, Houston, TX, 77030, USA. sneelapu@mdanderson.org.
Abstract
PURPOSE OF REVIEW: Chimeric antigen receptor (CAR) T cells are a form of adoptive therapy employing autologous T cells engineered with an artificial receptor, able to recognize tumor antigens through an HLA-independent mechanism. We will review data on safety and efficacy outcomes with CAR T cell therapy in lymphomas. RECENT FINDINGS: Multicenter trials evaluating three CAR T cell products targeting CD19 have shown that they are highly effective and induce durable remissions in a substantial proportion of patients with relapsed or refractory aggressive B cell non-Hodgkin lymphoma (NHL). The most common toxicities were cytokine release syndrome and neurotoxicity. Two anti-CD19 CAR T cell products were approved by the FDA for the treatment of patients with relapsed or refractory aggressive B cell NHL. Ongoing research is aimed at investigating their use in earlier lines of therapy and in other B cell lymphomas, improving CAR T cell efficacy and safety, and evaluating novel targets.
PURPOSE OF REVIEW: Chimeric antigen receptor (CAR) T cells are a form of adoptive therapy employing autologous T cells engineered with an artificial receptor, able to recognize tumor antigens through an HLA-independent mechanism. We will review data on safety and efficacy outcomes with CAR T cell therapy in lymphomas. RECENT FINDINGS: Multicenter trials evaluating three CAR T cell products targeting CD19 have shown that they are highly effective and induce durable remissions in a substantial proportion of patients with relapsed or refractory aggressive B cell non-Hodgkin lymphoma (NHL). The most common toxicities were cytokine release syndrome and neurotoxicity. Two anti-CD19 CAR T cell products were approved by the FDA for the treatment of patients with relapsed or refractory aggressive B cell NHL. Ongoing research is aimed at investigating their use in earlier lines of therapy and in other B cell lymphomas, improving CAR T cell efficacy and safety, and evaluating novel targets.
Entities:
Keywords:
Axicabtagene ciloleucel; CAR T cell therapy; CD19; Lymphoma; Tisagenlecleucel
Authors: Thomas M Habermann; Edie A Weller; Vicki A Morrison; Randy D Gascoyne; Peter A Cassileth; Jeffrey B Cohn; Shaker R Dakhil; Bruce Woda; Richard I Fisher; Bruce A Peterson; Sandra J Horning Journal: J Clin Oncol Date: 2006-06-05 Impact factor: 44.544
Authors: Karin C Straathof; Martin A Pulè; Patricia Yotnda; Gianpietro Dotti; Elio F Vanin; Malcolm K Brenner; Helen E Heslop; David M Spencer; Cliona M Rooney Journal: Blood Date: 2005-02-22 Impact factor: 22.113
Authors: A J Grillo-López; C A White; B K Dallaire; C L Varns; C D Shen; A Wei; J E Leonard; A McClure; R Weaver; S Cairelli; J Rosenberg Journal: Curr Pharm Biotechnol Date: 2000-07 Impact factor: 2.837
Authors: Michael B Jordan; Carl E Allen; Sheila Weitzman; Alexandra H Filipovich; Kenneth L McClain Journal: Blood Date: 2011-08-09 Impact factor: 22.113
Authors: Barbara Savoldo; Carlos Almeida Ramos; Enli Liu; Martha P Mims; Michael J Keating; George Carrum; Rammurti T Kamble; Catherine M Bollard; Adrian P Gee; Zhuyong Mei; Hao Liu; Bambi Grilley; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner; Gianpietro Dotti Journal: J Clin Invest Date: 2011-04-11 Impact factor: 14.808
Authors: Michael C Jensen; Leslie Popplewell; Laurence J Cooper; David DiGiusto; Michael Kalos; Julie R Ostberg; Stephen J Forman Journal: Biol Blood Marrow Transplant Date: 2010-03-19 Impact factor: 5.742
Authors: James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg Journal: Blood Date: 2010-07-28 Impact factor: 22.113
Authors: Cesar Clavijo Simbaqueba; Maria Patarroyo Aponte; Peter Kim; Anita Deswal; Nicolas L Palaskas; Cezar Iliescu; Eiman Jahangir; Eric H Yang; Raphael E Steiner; Juan Lopez-Mattei Journal: J Immunother Precis Oncol Date: 2020-07-20
Authors: George Yang; Matthew Mills; Youngchul Kim; Nicholas B Figura; Catherine Doyle; Daniel Oliver; G Daniel Grass; Timothy Robinson; Julio Chavez; Sungjune Kim Journal: Blood Cancer J Date: 2020-01-02 Impact factor: 11.037
Authors: Paolo Strati; Ankur Varma; Sherry Adkins; Loretta J Nastoupil; Jason Westin; Fredrick B Hagemeister; Nathan H Fowler; Hun J Lee; Luis E Fayad; Felipe Samaniego; Sairah Ahmed; Yiming Chen; Sandra Horowitz; Sara Arafat; Swapna Johncy; Partow Kebriaei; Victor Eduardo Mulanovich; Ella Ariza Heredia; Sattva S Neelapu Journal: Haematologica Date: 2021-10-01 Impact factor: 9.941